|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2009-9-2
|
|
pubmed:abstractText |
The insulin-like growth factor (IGF) signaling axis is frequently dysregulated in hepatocellular carcinoma (HCC). Therefore, we investigated whether the specific targeting of the IGF type 1 receptor (IGF-1R) might represent a new therapeutic approach for this tumor.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-3,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5445-56
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19706799-Antibiotics, Antineoplastic,
pubmed-meshheading:19706799-Antibodies, Monoclonal,
pubmed-meshheading:19706799-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19706799-Antineoplastic Agents,
pubmed-meshheading:19706799-Carcinoma, Hepatocellular,
pubmed-meshheading:19706799-Cell Line, Tumor,
pubmed-meshheading:19706799-Cell Survival,
pubmed-meshheading:19706799-Drug Resistance, Neoplasm,
pubmed-meshheading:19706799-Drug Synergism,
pubmed-meshheading:19706799-Humans,
pubmed-meshheading:19706799-Insulin,
pubmed-meshheading:19706799-Liver Neoplasms,
pubmed-meshheading:19706799-Phosphorylation,
pubmed-meshheading:19706799-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:19706799-Quinazolines,
pubmed-meshheading:19706799-RNA, Small Interfering,
pubmed-meshheading:19706799-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19706799-Receptor, IGF Type 1,
pubmed-meshheading:19706799-Receptor, erbB-3,
pubmed-meshheading:19706799-Signal Transduction,
pubmed-meshheading:19706799-Sirolimus
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
|
|
pubmed:affiliation |
UPMC Univ Paris 06, Paris, France. christele.desbois-mouthon@inserm.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
